Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

NCT01593228 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: Iniparib (SAR240550/BSI-201)
DRUG: Carboplatin
DRUG: Doxorubicin HCL liposome injection
DRUG: Gemcitabine
DRUG: Irinotecan
DRUG: Paclitaxel
DRUG: Topotecan

Sponsor

Sanofi